NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

神經肽Y受體2型:開發中產品分析

Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 520773
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
神經肽Y受體2型:開發中產品分析 Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2020
出版日期: 2020年10月30日內容資訊: 英文 39 Pages
簡介

本報告提供以神經肽Y受體2型為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

神經肽Y受體2型;概要

神經肽Y受體2型;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Gila Therapeutics Inc
  • Novo Nordisk A/S
  • XL-protein GmbH

藥物簡介

暫停中的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2608TDB

Summary:

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Furthermore, this report also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Overview
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Companies Involved in Therapeutics Development
  • CombiGene AB
  • Gila Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • XL-protein GmbH
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drug Profiles
  • CG-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GT-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PYY-1119 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Dormant Products
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Discontinued Products
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 01, 2020: CombiGene one step closer to clinical trials
  • Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies
  • Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene's AAV-based gene therapy for the treatment of epilepsy
  • Sep 11, 2020: CombiGene's new agreement important for future clinical studies
  • Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen
  • Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene's epilepsy gene therapy drug candidate
  • Aug 10, 2020: CombiGene has completed a successful pilot production of CG01 using Viralgen's suspension manufacturing platform
  • Aug 06, 2020: Results from CombiGene's cell tropism study confirm that CG01 only reaches the nerve cells in the hippocampus
  • Jul 13, 2020: Cobra Biologics delivers final plasmids for production of CG01 in CombiGene's epilepsy project
  • Mar 24, 2020: CombiGene has concluded a successful learning and memory study in the CG01 epilepsy project.
  • Mar 20, 2020: CombiGene has concluded the planned pharmacokinetic study in the CG01 epilepsy project with promising results.
  • Jan 21, 2020: CombiGene receives the second instalment of EUR 1.21 million from Horizon 2020
  • Dec 19, 2019: Study in human brain tissue shows that NPY can suppress epileptic activity via Y2-receptor activation
  • Nov 18, 2019: CombiGene receives a second payment of EUR 1.21 million from Horizon 2020
  • Nov 06, 2019: CombiGene: Two significant steps towards the first human studies for CG01
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by CombiGene AB, H2 2020
  • Pipeline by Gila Therapeutics Inc, H2 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
  • Pipeline by XL-protein GmbH, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020